v3.22.2.2
Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]    
Net revenue $ 1,022.0 $ 1,025.0
Segment Reporting Information Unallocated Expense [1] (87.0) (56.0)
Biologics    
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]    
Net revenue 523.0 548.0
Segment EBITDA 113.0 167.0
PharmaConsumerHealth    
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]    
Net revenue 499.0 477.0
Segment EBITDA 108.0 99.0
Total Catalent sub-total of Segment Reporting [Member]    
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]    
Segment EBITDA $ 221.0 $ 266.0
[1] Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: